Paying users zone. Data is hidden behind: .
Get 1-month access to Vertex Pharmaceuticals Inc. for $13.99, or
get full access to the entire website for at least 3 months from $49.99.
We accept:
This is a one-time payment. There is no automatic renewal.
Vertex Pharmaceuticals Inc. pages available today for free:
Enterprise Value to FCFF (EV/FCFF)
Free Cash Flow to The Firm (FCFF)
Vertex Pharmaceuticals Inc., FCFF calculation
US$ in thousands
Based on: 10-K (filing date: 2021-02-11), 10-K (filing date: 2020-02-13), 10-K (filing date: 2019-02-13), 10-K (filing date: 2018-02-15), 10-K (filing date: 2017-02-23).
Item | Description | The company |
---|---|---|
FCFF | Free cash flow to the firm is the cash flow available to the Vertex Pharmaceuticals Inc.’s suppliers of capital after all operating expenses have been paid and necessary investments in working and fixed capital have been made. | Vertex Pharmaceuticals Inc.’s FCFF increased from 2018 to 2019 and from 2019 to 2020. |
Interest Paid, Net of Tax
Vertex Pharmaceuticals Inc., interest paid, net of tax calculation
US$ in thousands
Based on: 10-K (filing date: 2021-02-11), 10-K (filing date: 2020-02-13), 10-K (filing date: 2019-02-13), 10-K (filing date: 2018-02-15), 10-K (filing date: 2017-02-23).
2 2020 Calculation
Cash paid for interest, tax = Cash paid for interest × EITR
= × =
Enterprise Value to FCFF Ratio, Current
Vertex Pharmaceuticals Inc., current EV/FCFF calculation, comparison to benchmarks
Selected Financial Data (US$ in thousands) | |
Enterprise value (EV) | |
Free cash flow to the firm (FCFF) | |
Valuation Ratio | |
EV/FCFF | |
Benchmarks | |
EV/FCFF, Competitors1 | |
Abbott Laboratories | |
AbbVie Inc. | |
Amgen Inc. | |
Bristol-Myers Squibb Co. | |
Eli Lilly & Co. | |
Gilead Sciences Inc. | |
Illumina Inc. | |
Johnson & Johnson | |
Merck & Co. Inc. | |
Pfizer Inc. | |
Regeneron Pharmaceuticals Inc. | |
Zoetis Inc. | |
EV/FCFF, Sector | |
Pharmaceuticals & Biotechnology | |
EV/FCFF, Industry | |
Health Care |
Based on: 10-K (filing date: 2021-02-11).
1 Click competitor name to see calculations.
If the company EV/FCFF is lower then the EV/FCFF of benchmark then company is relatively undervalued.
Otherwise, if the company EV/FCFF is higher then the EV/FCFF of benchmark then company is relatively overvalued.
Enterprise Value to FCFF Ratio, Historical
Vertex Pharmaceuticals Inc., historical EV/FCFF calculation, comparison to benchmarks
Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||
Enterprise value (EV)1 | ||||||
Free cash flow to the firm (FCFF)2 | ||||||
Valuation Ratio | ||||||
EV/FCFF3 | ||||||
Benchmarks | ||||||
EV/FCFF, Competitors4 | ||||||
Abbott Laboratories | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Illumina Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Zoetis Inc. | ||||||
EV/FCFF, Sector | ||||||
Pharmaceuticals & Biotechnology | ||||||
EV/FCFF, Industry | ||||||
Health Care |
Based on: 10-K (filing date: 2021-02-11), 10-K (filing date: 2020-02-13), 10-K (filing date: 2019-02-13), 10-K (filing date: 2018-02-15), 10-K (filing date: 2017-02-23).
3 2020 Calculation
EV/FCFF = EV ÷ FCFF
= ÷ =
4 Click competitor name to see calculations.
Valuation ratio | Description | The company |
---|---|---|
EV/FCFF | Enterprise value to free cash flow to the firm is whole company valuation indicator. | Vertex Pharmaceuticals Inc.’s EV/FCFF ratio increased from 2018 to 2019 but then decreased significantly from 2019 to 2020. |